, neurotransmitters, or amines in response to a variety of physiological and pharmacological stimuli. Nine members of the granin family have been presently described: chromogranins, namely chromogranins A (CgA) and B (CgB), and secretogranins, namely SgII, 1B1075
Biological function and clinical relevance of chromogranin A and derived peptides
Maria Angela D'amico, Barbara Ghinassi, Pascal Izzicupo, Lamberto Manzoli, and A Di Baldassarre
Plasma chromogranin A is a marker of death in elderly patients presenting with symptoms of heart failure
Jens P Goetze, Linda M Hilsted, Jens F Rehfeld, and Urban Alehagen
from the adrenal medulla is chromogranin A, or CgA (1) . CgA measurement in plasma has a central role in the diagnosis and treatment follow-up of neuroendocrine tumors, since these tumors often produce vast amounts of CgA (2, 3, 4) . In the
Chromogranin A, Ki-67 index and IGF-related genes in patients with neuroendocrine tumors
R C S van Adrichem, L J Hofland, R A Feelders, M C De Martino, P M van Koetsveld, C H J van Eijck, R R de Krijger, D M Sprij-Mooij, J A M J L Janssen, and W W de Herder
Introduction Gastroenteropancreatic neuroendocrine tumors (GEP NETs) are rare and heterogeneous tumors which may vary according to their biological, functional, and clinical behavior (1) . Chromogranin A (CgA) and the Ki-67 proliferation index are
A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors
Irvin M Modlin, Harry Aslanian, Lisa Bodei, Ignat Drozdov, and Mark Kidd
has remained a substantial technical challenge. A diverse variety of potential biomarkers has been proposed to be of utility in NET disease (2, 3, 4, 5) . These include the constitutive neurosecretory protein chromogranin A (CgA) as well as individual
Prognostic value of chromogranin A in patients with GET/NEN in the pancreas and the small intestine
Małgorzata Fuksiewicz, Maria Kowalska, Agnieszka Kolasińska-Ćwikła, Jarosław B Ćwikła, Łukasz Sawicki, Katarzyna Roszkowska-Purska, Joanna Drygiel, and Beata Kotowicz
monitoring use the ability of NEN cells to release non-specific markers into the bloodstream. The determination of non-specific marker – chromogranin A (CgA) – is applied in clinical practice ( 2 , 3 ). This substance belongs to acid glycoproteins
NETest is superior to chromogranin A in neuroendocrine neoplasia: a prospective ENETS CoE analysis
Anna Malczewska, Kjell Oberg, and Beata Kos-Kudla
prognostic studies (REMARK) . Journal of the National Cancer Institute 2005 97 1180 – 1184 . ( https://doi.org/10.1093/jnci/dji237 ) 5 O'Connor DT Bernstein KN Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic
Effect of A549 neuroendocrine differentiation on cytotoxic immune response
Irasema Mendieta, Rosa Elvira Nuñez-Anita, Gilberto Pérez-Sánchez, Lenin Pavón, Alfredo Rodríguez-Cruz, Guadalupe García-Alcocer, and Laura Cristina Berumen
-like structures ( 5 ). Such tumours also express neuroendocrine markers such as chromogranin A (CgA) ( 6 ), synaptophysin, neuronal enolase and CD56 ( 7 , 8 , 9 , 10 ). A key aspect of the neuroendocrine phenotype is the formation of granules that secrete
High-soluble CGA levels are associated with poor survival in bladder cancer
T Szarvas, B Jardin-Watelet, N Bourgoin, M J Hoffmann, P Nyirády, C Oláh, T Széll, A Csizmarik, B Hadaschik, and H Reis
Introduction Chromogranin A (CGA) is a 49 kDa glycoprotein encoded by the chromogranin A gene on chromosome 14q32.12. It belongs to the granin family of secretory proteins that are ubiquitous in the nervous, endocrine and immune systems. It is
GNEN-1: a spontaneously immortalized cell line from gastric neuroendocrine neoplasia
Klaus W Fagerstedt, Tom Böhling, Harri Sihto, Tarja Salonen, Fang Zhao, Mia Kero, Leif C Andersson, and Johanna Arola
with chromogranin A. Clear granular cytoplasmic staining can be seen as well as one mitotic figure (asterisk). All the scale bars represent 100 µm. GNEN-1 cells growth in semi-solid matrix, Matrigel ® GNEN-1 cells were first grown into
Plasma acylated and plasma unacylated ghrelin: useful new biomarkers in patients with neuroendocrine tumors?
Roxanne C S van Adrichem, Aart Jan van der Lely, Martin Huisman, Piet Kramer, Richard A Feelders, Patric J D Delhanty, and Wouter W de Herder
, nondiabetic NET patients ( N =28) and age- (±3 years) and sex-matched nonobese, nondiabetic controls ( N =28); and (ii) study the relationship between AG, UAG, and AG/UAG ratios and biochemical (chromogranin-A (CgA) and neuron-specific enolase (NSE) levels
